[
  {
    "ts": null,
    "headline": "Walgreens shareholders approve $10 billion private equity buyout",
    "summary": "Shareholders of Walgreens Boots Alliance overwhelmingly approved the drugstore chain's $10 billion acquisition by private equity firm Sycamore.  It is a rough era for national pharmacy chains like Walgreens, CVS, and Rite-Aid, closing hundreds of stores due to changing consumer behavior, declining pharmacy reimbursements and rising costs.  Walgreens will close more than 1,000 stores through 2027 and Rite-Aid filed for bankruptcy protection in May, it's second trip to bankruptcy court in as many years.",
    "url": "https://finnhub.io/api/news?id=c810fd22939df31970f04c226b76667f459d08243e2e6016007e2b0f5ea87dbc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752250071,
      "headline": "Walgreens shareholders approve $10 billion private equity buyout",
      "id": 135883825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Shareholders of Walgreens Boots Alliance overwhelmingly approved the drugstore chain's $10 billion acquisition by private equity firm Sycamore.  It is a rough era for national pharmacy chains like Walgreens, CVS, and Rite-Aid, closing hundreds of stores due to changing consumer behavior, declining pharmacy reimbursements and rising costs.  Walgreens will close more than 1,000 stores through 2027 and Rite-Aid filed for bankruptcy protection in May, it's second trip to bankruptcy court in as many years.",
      "url": "https://finnhub.io/api/news?id=c810fd22939df31970f04c226b76667f459d08243e2e6016007e2b0f5ea87dbc"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Add Cencora Stock to Your Portfolio Now",
    "summary": "COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.",
    "url": "https://finnhub.io/api/news?id=ae8e744b7f289f2dc99898dc01c2692024cccedf72ae10dafa8e0c28087f8c9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752235320,
      "headline": "Here's Why You Should Add Cencora Stock to Your Portfolio Now",
      "id": 135880118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.",
      "url": "https://finnhub.io/api/news?id=ae8e744b7f289f2dc99898dc01c2692024cccedf72ae10dafa8e0c28087f8c9b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.",
    "summary": "The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.",
    "url": "https://finnhub.io/api/news?id=e6b663a242acdabc7cbd8b56cfe95bc822c6f6a073bcfb8740e38f53b68a8d2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752220800,
      "headline": "Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.",
      "id": 135872906,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.",
      "url": "https://finnhub.io/api/news?id=e6b663a242acdabc7cbd8b56cfe95bc822c6f6a073bcfb8740e38f53b68a8d2c"
    }
  }
]